For patients with BRAF-mutated MM without any response to immunotherapy or with recurrence, the combination of BRAF- and MEK-inhibitors is a promising alternative, as was shown in a recent study on binimetinib [16]. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.